Photodynamic Therapy for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
- Author:
Hyeong Gon YU
1
;
Se Woong KANG
;
Woo Ho NAM
;
Hyoung Jun KOH
;
Hyung Woo KWAK
;
Oh Woong KWON
;
Si Yeol KIM
;
In Taek KIM
;
Ha Kyoung KIM
;
Hyun Woong KIM
;
Young Jung ROH
;
Jun Woong MOON
;
Kyu Hyung PARK
;
Suk Ho BYEON
;
Su Jeong SONG
;
Jae Kyoun AHN
;
Boo Sup OUM
;
Jae Ryung OH
;
Seung Young YU
;
Ill Han YOON
;
Sung Chul LEE
;
Won Ki LEE
;
Jae Heung LEE
;
Jeong Hee LEE
;
Ji Eun LEE
;
Tae Gon LEE
;
Gwang Ju CHOI
;
Don Il HAM
;
Kuhl HUH
;
Hum CHUNG
Author Information
1. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. chungh@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Age-related macular degeneration (AMD);
Choroidal neovascularization (CNV);
Photodynamic therapy (PDT)
- MeSH:
Choroid*;
Choroidal Neovascularization*;
Follow-Up Studies;
Humans;
Korea;
Macular Degeneration*;
Photochemotherapy*;
Prognosis;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2007;48(6):789-798
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate the effects of repeated photodynamic therapy (PDT) for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) in Korean patients. METHODS: Clinical data of patients who were treated with repeated (3 times or more) PDT for subfoveal choroidal neovascularization secondary to AMD and followed up for more than 6 months were collected from 17 hospitals around the country. Visual outcomes at 12 and 24 months, follow-up were compared between subtypes of choroidal neovascularization. The factors related to final visual prognosis and PDT-related adverse effects were evaluated. RESULTS: 244 patients (244 eyes) were recruited (male: 60%, age: 67.7+/-9.1 years). The portion of patients with predominantly classic, minimally classic, and occult without classic choroidal neovascularization was 57%, 13%, and 24%, respectively and that of patients with visual improvements or less than moderate visual loss at 24 months follow-up were 28%, 38%, 30% and 47%, 56%, and 65%, respectively. Baseline visual acuity and age were significantly related to the final visual prognosis (p<0.05). PDT-related adverse events developed in 15 (6.1%) patients, but most were mild and transient. CONCLUSIONS: Repeated PDT for subfoveal choroidal neovascularization secondary to AMD has effects comparable to those of previous prospective, controlled trials without any significant safety concerns in Korea.
